NAD+, NMN and NR are closely related, but they are not the same supplement. NAD+ is the coenzyme cells use directly in redox metabolism and many signaling reactions. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors the body can convert into NAD+ through different biochemical steps.
That distinction matters because the human evidence is not identical for all three. NR and NMN have a larger clinical literature showing that oral supplementation can raise NAD-related biomarkers. Direct oral NAD+ has historically had less human evidence, although a 2026 randomized trial of a specific modified NAD+ formulation reported a rapid increase in whole-blood intracellular NAD+. None of those findings should be treated as proof that every NAD-focused supplement produces the same result.
Key Takeaways
- NAD+ is the coenzyme itself, while NMN and NR are precursors used in NAD+ biosynthesis. All three sit within the same NAD metabolic network, but they enter it at different points.
- NR has strong human biomarker evidence. In an 8-week randomized trial, 100, 300 and 1,000 mg/day of NR increased whole-blood NAD+ by approximately 22%, 51% and 142%, respectively.
- NMN also raises blood NAD-related measures in human trials. A placebo-controlled trial using 250 mg/day for 12 weeks increased whole-blood NAD+, and a 2024 meta-analysis found an overall significant effect of NMN on blood NAD levels.
- Direct oral NAD+ evidence is newer and more formulation-specific. A 2026 randomized Phase 0/1b trial of a proprietary modified NAD+ formulation reported a 53% increase in whole-blood intracellular NAD+ versus placebo after five days, while plasma NAD+ did not increase.
- Raising an NAD biomarker is not the same as proving a longevity outcome. The strongest recent review of human NAD+ precursor trials concluded that biomarker changes are clearer than consistent improvements in clinical outcomes.
What Is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme found throughout the body. It participates in oxidation-reduction reactions that help transfer electrons from nutrients into pathways that ultimately support ATP production.
NAD+ also acts as a substrate for enzymes involved in metabolic regulation, stress responses and DNA-damage signaling, including sirtuins and PARPs. That broader biology is why NAD+ metabolism has become a major focus of healthy-aging research.
For the deeper cellular-energy context—mitochondria, ATP, the NAD+/NADH cycle and what human research shows with age—read our Cellular Energy Explained guide.
What Is NMN?
NMN (nicotinamide mononucleotide) is an intermediate in NAD+ biosynthesis. Cells can convert NMN into NAD+ through the enzyme NMNAT. Oral NMN has therefore been studied as a way to influence NAD metabolism without consuming NAD+ itself.
Human trials have generally focused on blood NAD-related biomarkers, metabolic measures, physical-performance outcomes and short-term tolerability.
What Is NR?
NR (nicotinamide riboside) is another NAD+ precursor. NR is converted to NMN by nicotinamide riboside kinases and can then be converted to NAD+.
NR has been studied extensively in humans, including dose-ranging trials measuring whole-blood NAD+ and downstream metabolites. Like NMN, the clearest repeated finding is that supplementation can change NAD-related biomarkers. Whether those biomarker changes translate into meaningful clinical outcomes depends on the population, endpoint and study design.
NAD+ vs NMN vs NR: The Core Difference
| Compound | What it is | How it relates to NAD+ | Human evidence focus |
|---|---|---|---|
| NAD+ | The coenzyme itself | Direct NAD+ rather than a precursor | Historically limited oral evidence; newer formulation-specific human data are emerging |
| NMN | NAD+ precursor | Converted to NAD+ through NMNAT | Blood NAD biomarkers, metabolic outcomes, physical performance, safety |
| NR | NAD+ precursor | Converted to NMN, then NAD+ | Blood NAD biomarkers, metabolism, inflammation and other clinical endpoints |
What Human Research Shows for NR
Randomized trial: dose-dependent increases in whole-blood NAD+
An 8-week randomized, double-blind, placebo-controlled trial studied NR in overweight but otherwise healthy adults. Participants received 100, 300 or 1,000 mg/day.
Whole-blood NAD+ increased in a dose-dependent manner by approximately 22%, 51% and 142%, respectively, within two weeks, and the increases were maintained through the study. The researchers reported no significant difference in adverse events between NR and placebo groups. Read the trial on PubMed.
This is strong evidence that oral NR can alter systemic NAD metabolism. It is not, by itself, proof of improved energy, performance or lifespan.
What Human Research Shows for NMN
250 mg/day for 12 weeks increased whole-blood NAD+
A randomized, double-blind, placebo-controlled study enrolled 30 healthy adults. Participants received 250 mg/day of NMN or placebo for 12 weeks.
The NMN group showed a significant increase in whole-blood NAD+ and no obvious adverse effects in the study period. Read the trial on PubMed.
What meta-analyses add
A systematic review and meta-analysis published online in 2024 and in its final journal issue in 2025 evaluated 12 studies with 513 participants and found that NMN supplementation had an overall significant effect on raising blood NAD levels. View the meta-analysis on PubMed.
However, biomarker improvement should not be confused with broad metabolic improvement. A separate 2024 meta-analysis of eight randomized trials involving 342 middle-aged or older adults found no significant overall benefit for fasting glucose, fasting insulin, HbA1c, HOMA-IR or lipid profile. Read the metabolic meta-analysis.
That pattern is important: NMN can influence NAD-related biomarkers, while downstream clinical effects are more variable.
What Human Research Shows for Direct Oral NAD+
Direct oral NAD+ has had a smaller human evidence base than NR and NMN, and the formulation matters.
A 2026 double-blind, randomized, placebo-controlled Phase 0/1b trial evaluated a specific proprietary modified oral NAD+ formulation called LathMized® NAD+ (LNAD+) in healthy adults aged 45–75. Sixty people were randomized, with 50 included in the primary analysis.
After five days, the treatment group showed a 53% increase in whole-blood intracellular NAD+ versus placebo at day 6. Plasma NAD+ itself did not increase. The intervention was well tolerated over the short study period, but no secondary clinical, vital-sign, wellbeing or wearable-derived endpoint remained significant after correction for multiple comparisons. Read the 2026 trial on PubMed.
This result is formulation-specific. The study tested LNAD+, not every oral NAD+ capsule on the market. It therefore provides proof that a particular oral NAD+ formulation can alter whole-blood intracellular NAD+, but it should not be generalized to unrelated finished products without their own data.
Study context: the publication discloses financial relationships between several authors and BioNADRx, including stock options, shares, consulting roles or investment. That does not invalidate the randomized results, but it is relevant context when interpreting a proprietary-formulation study.
Which Has the Strongest Human Evidence?
It depends on what outcome you mean.
- For increasing blood NAD-related biomarkers: NR and NMN currently have the broader human clinical literature.
- For direct oral NAD+: human evidence is emerging, including the 2026 LNAD+ trial, but it is less extensive and more formulation-specific.
- For proven longevity or broad anti-aging outcomes: none of the three has established that claim in humans.
A 2025 review in Nature Metabolism assessed the human clinical literature on NAD+ precursors and concluded that the published evidence remains tissue-specific and that human trials have so far shown limited efficacy for broad healthy-aging outcomes despite strong preclinical rationale. Read the review on PubMed.
Does NAD+ Automatically Decline With Age?
No single decline curve applies to the entire human body.
The 2025 Nature Metabolism review found that consistent age-related reductions in human NAD+ had been demonstrated in only a limited number of studies and tissues. A 2026 study across seven independent human cohorts also reported that whole-blood NAD+ remained stable with age and across lifestyle interventions, while still responding to NR supplementation.
The most accurate conclusion is that NAD metabolism can change with age in a tissue-specific way; claims that everyone loses a fixed percentage of NAD+ by a certain age are too simplistic.
How to Compare NAD+, NMN and NR Supplements
- Identify the exact compound. “NAD support” is not specific enough. Check whether the label contains direct NAD+, NMN, NR or another ingredient.
- Check the amount per full serving. Compare the daily serving, not only the amount per capsule.
- Match the formulation to the evidence. A study on one proprietary delivery system does not automatically validate every formulation containing the same headline ingredient.
- Separate biomarkers from outcomes. Raising blood NAD+ is a measurable biological effect; improved energy, performance, cognition or longevity are separate claims requiring separate evidence.
- Look for transparent labeling. Exact ingredient identity, standardized botanical extracts where applicable, serving size and directions should be easy to find.
What About Safety?
Short-term human trials of NR and NMN have generally reported good tolerability at studied doses. The 2026 LNAD+ trial also reported favorable short-term tolerability for that specific direct-NAD+ formulation.
That does not mean every product or every dose has identical safety. Long-term clinical data remain more limited than short-term biomarker studies. If you take prescription medication, are pregnant or breastfeeding, have a medical condition, or are preparing for surgery, discuss the specific supplement with a qualified healthcare professional.
What Is FDA's Current Position on NMN in Dietary Supplements?
FDA's position changed in 2025. In its final response to citizen petitions, the agency stated that it no longer considers NMN excluded from the dietary supplement definition under the drug-exclusion provision because it determined that NMN had been marketed as a dietary supplement in the United States before authorization for drug investigation.
That conclusion is not the same as FDA approval of an NMN product, and manufacturers remain responsible for meeting applicable dietary-supplement requirements. Read the FDA response.
Frequently Asked Questions
Is NAD+ the same as NMN?
No. NAD+ is the coenzyme itself. NMN is a precursor that can be converted into NAD+ inside the body.
Is NMN the same as NR?
No. They are different molecules in the NAD biosynthesis pathway. NR is converted to NMN, which can then be converted to NAD+.
Do NMN and NR raise NAD+ in humans?
Yes, human trials show that both can increase blood NAD-related measures. The size of the effect varies by dose, population, study duration and measurement method.
Can oral NAD+ itself raise NAD+?
A 2026 randomized trial showed that a specific modified oral NAD+ formulation increased whole-blood intracellular NAD+. That finding is important, but it is formulation-specific and should not be assumed to apply to every direct NAD+ supplement.
Does raising NAD+ mean you will live longer?
No human trial has established that taking NAD+, NMN or NR extends human lifespan. Biomarker changes and longevity outcomes are different questions.
Which one should I choose?
Start with your actual goal and then compare the evidence for the specific compound and formulation. NR and NMN currently have broader human biomarker evidence; direct oral NAD+ evidence is newer and more formulation-specific. Product quality, dose transparency and realistic claims matter as much as the ingredient name.
The Bottom Line
NAD+, NMN and NR belong to the same metabolic system, but they are not interchangeable. NR and NMN are precursors with a comparatively larger human literature showing increases in NAD-related biomarkers. Direct oral NAD+ has a smaller evidence base, although new formulation-specific clinical data show that direct oral NAD+ can influence intracellular NAD in whole blood under studied conditions.
The most important distinction is between biological activity and proven outcomes. Changing an NAD biomarker is meaningful evidence of metabolic engagement; claims about energy, cognition, performance or longevity require their own human data.
Explore a Direct NAD+ Formula
If you specifically prefer a formula built around direct NAD+ rather than NMN or NR, you can review the transparent Supplement Facts for AgeCore NAD+™. Each labeled serving provides 500 mg NAD+ alongside 250 mg Quercetin Dihydrate Extract and 150 mg Japanese Knotweed Extract standardized to 98% Resveratrol.
AgeCore NAD+™ is not the LNAD+ formulation used in the 2026 clinical trial described above, and IDRAK does not present that study as proof of the finished AgeCore formula.
References
- Vinten KT, Trętowicz MM, Coskun E, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nature Metabolism. 2025;7(10):1974-1990. PMID: 41083806.
- Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. 2019. PMID: 31278280.
- Okabe K, Yaku K, Uchida Y, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. 2022. PMID: 35479740.
- Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Critical Reviews in Food Science and Nutrition. 2025;65(22):4382-4400. Epub 2024. PMID: 39116016.
- Chen F, Zhou D, Kong APS, et al. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. 2024. PMID: 39531138.
- Kornilov SA, Hastings WJ, McGrath LF, et al. Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. GeroScience. 2026. PMID: 42530810.
- Gindri IM, Ferrari G, Pinto LPS, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. American Journal of Physiology-Endocrinology and Metabolism. 2024;326(4):E417-E427. PMID: 37971292.
- Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nature Metabolism. 2026;8(6):1282-1290. PMID: 42135539.
- U.S. Food and Drug Administration. Response regarding the dietary-supplement status of NMN under section 201(ff)(3)(B). 2025.
This article is for educational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the U.S. Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional before beginning a new supplement if you take prescription medication, have a medical condition, or are pregnant or breastfeeding.